A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors

Summary

This first-in-human open-label, multicenter, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and primary efficacy of IBI321 in participants with locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable.

Timeline

Start

2021-06-21

Primary completion

2023-01-30

Completion

2023-02-17

Drugs

Indications